Clinical Trials
Japanese encephalitis vaccine shows positive results in pivotal Phase III safety trial
Published in Biotech Business Week, September 25th, 2006
The pivotal Phase III safety trial was conducted at 39 study sites in Austria, Germany, Romania, Israel, Australia, New Zealand and in the U.S. and included 2,683 randomized subjects. The study was designed to analyze the safety and tolerability of Intercell's investigational vaccine in a multicenter, multinational, double-blind, placebo-controlled randomized study.
Major endpoints of this study were the frequency of adverse events in both test groups, as well as local tolerability findings in both...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Healthcare Costs
Survey forecasts health plan costs down but drug plan costs to outpace inflation in 2007 - Market Analysis
Booming European enteral nutrition market provides opportunities for ingredient suppliers - Market Analysis
Global market for DNA oligos tops $700 million annually - Market Analysis
Research and Markets report finds healthcare in China to be extremely uneven - Neuroscience
Alzheimer, Parkinson, dementia targeted in protein study - Alzheimer Disease
Accera initiates phase II trial for age associated memory impairment therapy - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
